Methylene blue dosing strategies in critically ill adults with shock—A retrospective cohort study

BACKGROUND: Shock increases mortality in the critically ill and the mainstay of therapy is the administration of vasopressor agents to achieve hemodynamic targets. In the past, studies have found that the NO-pathway antagonist methylene blue improves hemodynamics. However, the optimal dosing strateg...

Descripción completa

Detalles Bibliográficos
Autores principales: Sari-Yavuz, Sibel, Heck-Swain, Ka-Lin, Keller, Marius, Magunia, Harry, Feng, You-Shan, Haeberle, Helene A., Wied, Petra, Schlensak, Christian, Rosenberger, Peter, Koeppen, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650001/
https://www.ncbi.nlm.nih.gov/pubmed/36388905
http://dx.doi.org/10.3389/fmed.2022.1014276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650001/
https://www.ncbi.nlm.nih.gov/pubmed/36388905
http://dx.doi.org/10.3389/fmed.2022.1014276

Ejemplares similares